Evaluation in Real Life Conditions of Sacubitril-valsartan Combination in Patients With Chronic Heart Failure and Sleep Apnea Syndrome
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Chronic heart failure; Sleep apnoea syndrome
- Focus Therapeutic Use
- Acronyms ENTRESTO-SAS
- 22 Mar 2021 Status changed from active, no longer recruiting to completed.
- 11 Mar 2020 Planned End Date changed from 15 Dec 2019 to 15 Dec 2021.
- 11 Mar 2020 Planned primary completion date changed from 15 Dec 2019 to 15 Dec 2020.